Introduction {#Sec1}
============

Folate is an essential water-soluble B vitamin found in foods, including dark-green leafy vegetables and legumes. Folic acid is the synthetic form of the vitamin present in supplements and fortified foods, namely grains and cereals. Dietary folate exists in a reduced state with polyglutamate side chains requiring oxidation and hydrolysis for absorption, whereas folic acid exists as the oxidized pteroylmonoglutamate form making it readily bioavailable \[[@CR1]\]. Dietary folate bioavailability ranges from 10 to 98% and is influenced by intestinal pH, enzymatic activity, presence of alcohol and other inhibitors, malabsorption disorders, and the food matrix \[[@CR1]\]. To account for the differences in absorption between folate and folic acid, folate equivalents are used. The recommended dietary allowance for adults in the USA is set at 400 micrograms (mcg) of dietary folate equivalents (DFE). One microgram of DFE is equivalent to 1 mcg dietary folate, 0.6 mcg folic acid consumed with food, or 0.5 mcg supplemental folic acid on an empty stomach. The upper limit for folate is 1,000 mcg/day, which is one fifth of the minimum amount known to mask a B~12~ deficiency \[[@CR2], [@CR3]\]. About 5% of the US population gets more than the upper limit, usually due to dietary supplements \[[@CR4]\]. There are several ways to assess folate status. Serum levels, are thought to reflect recent intake. Deficiency is categorized as less than 7 nmol/L to less than 10 nmol/L. Red blood cell (RBC) folate represents folate status over months with levels less than 315 to 363 nmol/L suggesting deficiency \[[@CR1], [@CR3], [@CR5]\]. Elevated urinary formiminoglutamate (FIGLU) excretion and deoxyuridine suppression tests are additional methods for assessing folate status. Also, elevated homocysteine may be a functional measure of folate status \[[@CR1]\].

Due to its role in one-carbon metabolism, folate has been studied extensively as a possible mechanism for cancer development. Folate as 5-Methyltetrahydrofolate (5-MTHF) and cobalamin are required for the conversion of homocysteine to methionine in the methionine pathway. Methionine is converted to *S*-adenosylmethionine (SAM). SAM is a chief methyl contributor to many reactions in the body, including DNA and RNA methylation \[[@CR6]\]. Inadequate production of SAM may lead to decreased methylation of CpG islands in DNA affecting gene transcription, altering expression of tumor suppressor genes and proto-oncogenes \[[@CR6], [@CR7]\]. Furthermore, folate deficiency can impair conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), the nucleic acid necessary for DNA synthesis and repair \[[@CR6], [@CR7]\]. The misincorporation of uracil for thymidine can eventually lead to unstable DNA, DNA strand breaks, and faulty DNA repair \[[@CR6], [@CR7]\].

Excess folate intake also poses a concern. Mandatory fortification of wheat flour and enriched cereal grain products aimed at reducing the incidence of neural tube defects has raised questions regarding growth of nascent cancers \[[@CR3]\]. Mandatory fortification has been in effect in the USA since 1998, and at least 87 countries have regulations in different stages of implementation \[[@CR8]\]. In the USA, a 140 mcg/100 g product is added to fortified foods and in some countries more is added; for example, Chile adds 220 mcg/100 g product \[[@CR3]\]. In addition, 35% of US adults may take a supplement containing 400 mcg folic acid, and in some countries, the frequency of people supplementing is even higher. Average total folate intake of 813 mcg/day for men and 724 mcg/day for women has been reported in the USA, with only 15--17% of adults not meeting the daily recommended amount \[[@CR4]\].

Folic acid, found in fortified foods and supplements, is converted to tetrahydrofolate in the liver by dihydrofolate reductase (DHFR). It has been reported that folic acid in excess of 400 mcg may saturate the DHFR enzyme, resulting in unreduced folic acid, which has been hypothesized as a potential mechanism for carcinogenesis \[[@CR3], [@CR9]•\].

Just as overt folate deficiency and excess intake may interfere with cell replication and survival, reduced enzyme efficiency can also interfere with nutrient metabolism and influence disease risk. Methylenetetrahydrofolate reductase (MTHFR) is a key flavoenzyme that catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF). It is encoded by the gene MTHFR. There are two well-described MTHFR gene polymorphisms: C677T and A1298C. The C677T variant may occur in close to 20--40% of the population \[[@CR12], [@CR53]\]. Both variants are associated with reduced enzyme activity \[[@CR11]\]. Enzyme efficiency is reduced by up to 45% for the 677CT variant and by up to 70% for 677TT \[[@CR10]\]. The variated form of the enzyme has less affinity to its cofactor, flavin adenine dinucleotide. Cytosolic serine hydroxy methyl transferase (SHMT1) is another key enzyme in folate metabolism. It converts serine and tetrahydrofolate to glycine and 5,10-methylenetetrahydrofolate, respectively. 5,10-methylenetetrahydrofolate is a substrate for purine and pyrimidine synthesis. The combination of folate deficiency and polymorphisms may result in DNA hypo- \[[@CR12]\] or hypermethylation \[[@CR13]\].

The relationship between folate and cancer risk remains uncertain, as studies have demonstrated positive, negative, and neutral associations. Also of note, antifolates are used in cancer treatment, however that is outside of the scope of this review. Therefore, the purpose of this paper is to summarize current knowledge of folate's impact on cancer risk and identify opportunities for future work in this area based on a review of meta-analyses from the past 5 years. Many factors contribute to the findings, including the type and dose of the vitamin (dietary, supplemental, and total), serum levels and method of evaluating, cancer type and presence of gene polymorphisms.

Methods {#Sec2}
=======

This review was conducted to evaluate the impact of folate on cancer risk. PubMed/MEDLINE and the Cochrane database were searched by combining the key words "folate" or "folic acid" and "cancer risk." Meta-analyses published in the last 5 years in human adults and in English were included. Titles and abstracts were reviewed to select articles related to cancer risk in adults. Articles were excluded if they were related to cancer treatment, childhood cancer risk, or other disease states. Additional articles were obtained from references of relevant papers. A summary of the review articles selected is shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1Literature search of meta-analyses investigating folate and cancer risk in humansFirst author, referenceNumber of cases/controls (cohort)Cancer typeMeasurementsResultsChen P \[[@CR14]\]Folate intake and breast cancer riskBreast*Prospective studies*\
Dietary folate intakeNS16 prospective: 744,068 participants/26,205 breast cancerHigher total folate intakeNSU-shaped26 case-control: 16,826 cases/21,820 controls.Dose-responseS: reduced risk with dietary folate intake 153--400 mcg compared with those of \< 153 mcg.\
NS: reduced risk with intake \> 400 mcg compared to \< 153 mcgSerum folate level and breast cancer risk\
8 studies: 5,924 participants*Case-control studies*\
Dietary folate intakeS: reduced risk dietary folate intake highest category compared to lowest category\
NS when adjusted for publication biasHigher total folate intakeNSDose-responseS: increased intake of 100 mcg dietary folate per day showed reduced breast cancer riskZhang YF \[[@CR15]\]14 prospective observational studiesBreastFolate intakeNS677,858 participantsDose responseNS with 100 mcg per day; heterogeneity\
S: J-shape correlation between folate intake and breast cancer risk. Dietary folate intake 200--320 mcg was associated with lower breast cancer risk; risk increased with daily folate intake \> 400 mcgSubgroup analyses: country, study design, sample size, effect estimate, follow-up duration, adjusted alcohol intakeS: higher folate intake associated with reduced risk compared to lowest category if daily alcohol intake \> 10 g\
S: folate intake associated with increased risk when nested case-control studies included; 100 mcg per day increment in folate intake was associated with increased risk.Liu \[[@CR16]\]15 prospective cohort studies, 1 nested case-control study.BreastDietary folateNS1,854,013 participants and 24,620 breast cancer cases.Dose-responseNS: 220 mcg per day increment in dietary folate intake was not associated with breast cancer riskMenstrual status, hormonal status, and consumption of alcohol, methionine and vitamin B12.NSTio \[[@CR52]\]36 studies.BreastDietary folateNS: once adjusted608,265 sample size, 34,602 casesTotal folate intakeNSMenopausal statusNS once adjustedHormone statusNSStudy designS: retrospective study design showed decreased risk of postmenopausal breast cancerFan C \[[@CR18]\]4,090/10,902 9 case-control studies: 7 dietary folate with FFQ; 2 studies serum folate concentration; 4 studies dose-response analysisHead and neckFolate intakeS: decreased risk comparing highest to lowest folate intakeDose-responseS: every 100 mcg/day increase in folate intake associated with 4.3% decreased riskGaleone C \[[@CR19]\]5,127/13,249\
Pooled analysis of individual-level data from 10 case-control studiesOral cavity and pharyngeal (OPC)Total folate intakeS: Reduced risk for highest compared lowest quintile total folate intake and overall OPC risk\
S: decreased risk for oral cavityAlcoholS: increased risk for heavy drinkers with low folate intake compared to low alcohol intake with higher folate intakeSmokingS: increased risk for smokingZhao Y \[[@CR20]\]19 studiesEsophagealDietary folate intakeS: decreased risk with highest folate intake compared to lowest intake14 case-control 1 cohort dietary folate intake6 case-control 1 cohort for dose-responseDose-responseS: 100 mcg/day increment in dietary folate intake reduced risk by 12%Tio M \[[@CR21]\]9 case-control 2574/9254 for any histological type of esophageal cancer.Esophageal, gastric, pancreaticDietary folateS: dietary folate associated with decreased risk of esophageal and pancreatic cancer\
NS: gastric cancer8 studies (5 prospective, 3 retrospective) 2209/295,526 for pancreatic cancer.16 for gastric (3 prospective, 13 retrospective) 4414/209,689Lin HL \[[@CR22]\]13 studies with 14 estimates (7 cohort, 6 case-control); 10 for dietary folate; 5 supplemental; 4 total, 3 serumPancreaticDietary folate intakeS: decreased pancreatic cancer risk with highest dietary folate intake compared to lowest intake*N* = 3467SupplementalNS2 case-control, 5 cohort for dose-response analysisDose-responseS: decreased risk for pancreatic cancer with 100 mcg/day increase intakeZhang YF \[[@CR23]\]9 cohort studies with *n* = 566,921LungDietary folate intakeNSDose-responseNS per 100 mcg/day increaseDietary folate intakeS: low intake reduced risk of lung cancer in womenDietary folate intakeS: high intake reduced risk in menWang R \[[@CR24]\]10 with *n* = 202,517ProstateDietary folate intakeNS5 cohort dietary folateDose-responseNS: dose response of 100 mcg/dayTio M \[[@CR17]\]19 studiesProstateDietary folateNS: marginally decreased risk11 (5 cohort, 6 case-control) for dietary folate intake 15,336/146782Total folateNS: no association5 (2 cohort, 3 case-control) Total folate intake 7114/93781He H \[[@CR25]\]13 studies (7 cohort, 6 case-control) 6280 casesBladderTotal folate intakeS: decreased risk of bladder cancer associated with highest compared to lowest folate intake.Dietary folateS: decreased risk of bladder cancer with dietary folateStudy designS: inverse association between folate intake and bladder cancer in case-control studies; NS in cohort studiesLi C \[[@CR26]\]Folate intake: 8 studies highest quantile vs lowest folate intake and riskOvarianDietary folateS for high dietary folate and reduced risk when 1 study removed due to heterogeneity1158 cases out of 217,309 4 cohort studies folate intake\
4519/6031 case-control folate intakeTotal folateNSDu L \[[@CR27]\]9 case-control and 5 cohort studiesEndometrialTotal folateNSDose-responseS: in the highest category, 5% increased risk per 100 mcg/dayStudy designS: decrease risk of total folate intake in case-control studies; NS in cohort studiesCountryNS in North American studies; S: decrease risk of total folate intake in studies outside of North America (China, Mexico, Switzerland)S = statistically significant (*P* \< 0.05)NS = not statistically significant (*P* \> 0.05)Table 2Literature search of meta-analyses investigating serum folate levels, folate supplementation, gene polymorphisms, and cancer riskFirst author, referenceNumber of cases/controls (cohort)Cancer typeMeasurementsResultsChen P \[[@CR14]\]Serum folate level and breast cancer riskBreastSerum folateNS: prospective studies;NS: case-control studies8 studies: 5,924 participantsFolic acid supplementalNSFolate intake and breast cancer risk\
16 prospective:\
744,068 participants/26,205 breast cancer\
26 case-control: 16,826 cases/21,820 controls.Stratification: study quality, menopause status, estrogen receptor status, alcohol intake, race/ethnicityNS: prospective studies had heterogeneity for the summary estimate between the stratification;\
S: Case-control studies had reduced risk with higher dietary folate in Europe, Australia or Asia but not in the USA\
S: hospital-based studies suggested highest category of dietary folate intake showed reduced breast cancer risk; no association with population-based studies\
S: higher quality studies suggested higher folate intake may reduce breast cancer risk\
NS menopausal status\
S: increase dietary folate intake reduced breast cancer risk for women with higher alcohol intake, but no association for those with lower alcohol intakeTio \[[@CR52]\]36 studies.BreastSerum folateNS608,265 sample size, 34,602 casesZhao Y \[[@CR20]\]19 studies\
4 for serum folateEsophagealSerum folateS: decreased risk for highest vs lowest serum folateTio M \[[@CR21]\]9 case-control 2,574/9,254 for any histological type of esophageal cancer.Esophageal, gastric, pancreaticSerum folateNS: Serum levels and pancreatic cancer8 studies (5 prospective, 3 retrospective) 2,209/295,526 for pancreatic cancer.16 for gastric (3 prospective, 13 retrospective) 4,414/209,689Lin HL \[[@CR22]\]13 studies with 14 estimates (7 cohort, 6 case-control); 5 supplemental N = 3,467PancreaticSerum folateNS: decreased riskFolic acid supplementationS: decreased risk for 100 mcg/day increment increase intakeWang R \[[@CR24]\]10 studies. n = 202,517ProstateSerum folateS: high levels serum folate levels were associated with increased risk5 nested case-controlDose-responseS: 5 nmol/L increment associated with increased riskTio M \[[@CR17]\]7 (6 nested case-control, 1 case-control) 6,122/10,232ProstateSerum folateS: high levels associated with increased riskZhou X \[[@CR28]\]6 case-control 873/1,510CervicalSerum folateS: deficient serum folate levels and increased risk; S: increased risk if folate level ≤ 6.4 ng/ml; NS: If deficiency level ≥ 6.4 ng/mlSample sizeNS: studies with *n* ≥ 500; S: if sample size \< 500CountryNS: American studies; S: Asian studiesZhang D \[[@CR11]\]16 studies 5,657/6,557 MTHFR C677T, A1298C, G1793AOverall cancer riskSerum homocysteineS: increased risk with high homocysteineSerum folateS: increased risk with folate deficiencyS.Chuang \[[@CR29]\]8 publications (10 cohorts, representing 3,477 cases/7,039 controls)CRCSerum folateNS: higher levels compared to lowest and risk\
S: inverse association between circulating folate and CRC risk in studies that used the radioimmunoassay.D.Kennedy \[[@CR30]\]67 studies met criteria;\
62 case controlled, 2 cohort and 3 older versions retained for folate intake dataCRCMTHFR polymorphismsS: reduced risk of CRC with high total folate intake with 677TT genotype, 677CC\
NS: A1298CHe H \[[@CR25]\]13 studies (7 cohort, 6 case-control) 6,280 casesBladderFolic acid supplementationNSLi C \[[@CR26]\]Folate intake: 8 studies highest quantile vs lowest folate intake and riskOvarianFolic acid (fortified foods and supplements)NSMTHFR polymorphismsNS1,158 cases out of 217,309 four cohort studies folate intake\
4,519/6,031 case control folate intake\
5,617/9,808 polymorphismsMao B \[[@CR31]\]5 studies (7 cohorts) 2441/133,995RenalFolic acid supplementationS: decreased risk with increase of 100 mcg/day FA supplementation3 case-control; 2 cohort; 1 nested case control; 1 case cohortQin X \[[@CR32]•\]15 RCTs: 13 with total cancer incidence outcome and folic acid supplementationTotal incidence (13 trials, *n* = 49,406)\
Colorectal (7 trials, *n* = 33,824)\
Other GI (2 trials, n = 20,228)\
Prostate (5 trials, *n* = 27,065)\
Other GU (2 trials, n = 20,228)\
Lung (5 trials, *n* = 31,864)\
Breast (4 trials, *n* = 19,800)\
Heme (3 trials, *n* = 25,670)\
Total Cancer Mortality (6 trials, *n* = 31,930)\
Melanoma (3 trials, *n* = 19,128)Folic acid supplementationNS total cancer; colorectal; other GI; prostate; other GU; lung; breast; heme; total cancer mortality\
S: folic acid supplementation decreased risk of melanomaLipid-lowering drugsS: elevated risk with lipid-lowering drugsHypertensionNSVollsett SE \[[@CR33]•\]13 trials *N* = 49,621Overall cancer incidence from cardiovascular or colorectal adenoma prevention studies comparing folic acid to placebo over 5--6 yearsFolic acid supplementationNS: median dose of 2.0 mg folic acidWien TN \[[@CR34]•\]19 studies (12 RCT)Cancer risk associated withFolic acid supplementationS: increased risk in prostate cancer10 RCT for overall incidencefolic acid supplementationS: marginal increased risk in cancer incidence with FA6 RCT prostateS: increased incidence in prostate cancer with FA\
S: marginal increased risk in cancer mortality with FA\
S: increased risk if doses between 0.4 and 1 mg, but not if \> 1 mgGenderS: increased risk in studies with \> 70% malesCurrent smokersS: increased risk if \> 30% smokersFollow-up \< or \> 60 monthsS: increased risk if \> 60 months of follow-upT.Qin \[[@CR35]\]8 RCTCRCFolic acid supplementationNSR.Heine-Broring \[[@CR36]\]24--4 studies specific to folic acid (supplements and fortification)\
Systematic review and meta-analysis of prospective cohort studiesCRCFolic acid supplementationS: inverse association for highest vs lowest folic acid from supplements and colorectal cancer riskDose-responseNS: no association for increase of 100 mcg/day of folic acid from supplements and CRCY.Liu \[[@CR37]\]47 articles met inclusion criteria (19 studies relating to folate)CRCFolic acid supplementationS: reduced risk with highest compared to lowest intakeLi C \[[@CR26]\]MTHFR polymorphism: 10 studies with 12 subgroup studies: 5,617 cases/9808 controlsOvarianMTHFR polymorphismsNSZhang D \[[@CR11]\]16 studies 5,657/6,557 MTHFR C677T, A1298C, G1793AOverall cancer riskMTHFR C677T, A1298C, G1793AS: increased risk of C677T homogeneity and overall risk of cancerTang M \[[@CR38]\]134 case-control studiesMTHFR C677T and cancer riskT vs CS: increased risk46,207 cases and 69,160 controlsTC vs. CCNSTT vs CCS: increased riskTC + TT vs CCS: increased riskTT vs. TC + CCNSRace/ethnicityS: increased cancer risks were indicated among Asians in all genetic models except for heterozygote modelCancer typeS: increased risks of esophageal and stomach cancer were observed across modelsRai \[[@CR7]\]14 case-control studies 9,468 cases, 9,078 controlsMTHFR C677T, Lung Asian population, China, Japan, TaiwanT vs CS: increased riskCT vs CCNSTT vs CCS: increased riskTT + CT vs CCS: increased riskTT vs CT + CCS: increased riskRai \[[@CR12]\]36 case-control studies 8,040 cases, 10,008 controlsMTHFR C677T, Breast Asian population, Turkey, China, Korea, Taiwan, E.As, India, Singapore, Japan, Arab, Iran, Syria, PakistanT vs CS: increased riskCT vs CCNSTT vs CCS: increased riskTT + CT vs CCS: increased riskTT vs CT + CCS: increased riskKaya \[[@CR39]\]6 case-control studies 707 cases, 880 controlsMTHFR C677T, Breast Turkish populationsT vs CS: increased riskTT vs. CCS: increased riskTT + CT vs. CCNSTT vs. CT + CCS: increased riskYi \[[@CR40]\]12 case-control studies for C677TCervicalMTHFR C677TNS2,332 cases and 3,000 controls\
5 studies for A1298C polymorphisms\
677 cases and 1,191 controlsCaucasian, Asian, and mixed descent. Studies had been carried out in China, Korea, India, Greece, Germany, The Netherlands, and Poland.MTHFR A1298CS: increased cervical cancer risk was found in 3 models: allele contrast, heterozygote, and dominantRace/ethnicityS: increased cervical cancer risk among Asian descentLi \[[@CR26]\]5 population-based case-control studies, 5 hospital/clinic-based case-control studies, 1 nested case-control\
5,617 cases, 9,808 controlsMTHFR C677T, ovarianHeterozygote, homozygote, dominant, and recessive.NSRace/ethnicityAsian ethnicity was associated with increased ovarian cancer risk for dominant, recessive and homozygous modelsLu \[[@CR41]\]10 case-control studies 1,786 cases, 2,076 controlsMTHFR C677T, GliomaAllele contrast, heterozygote, homozygote, dominant, recessive.NSXu \[[@CR42]\]8 case-control studies 3,059 cases, 3,324 controlsMTHFR C677T, Primary brainT vs. CNSTC vs. CCSTT vs. CCNSTT + TC vs. CCSTT vs. CC + TCNSRace/EthnicityNS: Caucasians;\
S: increased risk between the MTHFR C677T variant and the risk for brain tumors across all 5 models in AsiansTumor typeS: increased risk of meningioma associated with TC carriers compared with the CC carriersLiang \[[@CR43]\]7 case-control studies 2,030 cases, 3,096 controlsMTHFR A1298C, Liver Caucasians, AsiansCC vs AAS: decreased riskCC vs AA + ACS: decreased riskRace/ethnicityS: homozygote genotype CC of MTHFR rs1801131 polymorphism was associated with decreased risk of liver cancer in AsiansQi \[[@CR44]\]7 case-control studies for C677T 5 case-control studies for A1298C Chinese populationHepatocellularMTHFR C677TS: MTHFR C677T polymorphism was significantly associated with susceptibility to HCC in Chinese populationMTHFR A1298CS: MTHFR A1298C polymorphism was associated with decreased risk of HCC in Chinese populationGuo \[[@CR45]\]23 studies 11,348 cases, 12,676 controlsProstateMTHFR C677TNSEthnicityS: decreased risk seen for Asians across all genetic modelsStudy designS: decreased risk in hospital-based studies for the homozygote and recessive models; in aggressive prostate cancer for the homozygote modelJia \[[@CR46]\]7 case-control studies 1,318 cases, 1,817 controlsMTHFR C677T, OralCT vs. CCNSRace/ethnicityS: decreased risk associated with Asians CT vs CCHospital-based studiesS: decreased risk in hospital-based studies TT vs. CC; CT vs. CC.AlcoholS: increased risk heavy vs. non-heavy drinkers T vs. C; TT vs. CC; TT vs. CC; TT vs. CT + CCDong \[[@CR47]\]8 case-control studies 1,114 cases, 3,227 controlsMyeloid leukemiaMTHFR A1298CNSRace/ethnicityS: increased risk for Asians CC vs. AC + AAYang \[[@CR48]\]4 case-control studies 360 cases, 900 controlsThyroidMTHFR C677TS: increased risk T vs. C; TT vs. CCIncluded populations among Iran, India, Turkey, and Saudi ArabiaHe \[[@CR49]\]25 studies for MTHFR C677T\
7,448 cases, 11,146 controls\
19 studies for the A1298C polymorphism 6,173 cases, 9,725 controlsMTHFR C677T, non-Hodgkin lymphomaAssociation between both MTHFR C677T and A1298C and susceptibility to NHL; genetic models analyzed include allele contrast, heterozygote, homozygote, dominant, recessiveNS for pooled analysisMTHFR A1298C, non-Hodgkin lymphomaRace/ethnicityS: increased risk in Caucasians TT vs. CC; T vs. CS: decreased risk in Asians TT vs. CC; CT + TT vs. CC; T vs. CTumor typeS: increased risk in Asians CC vs. AA; AC + CC vs. AA, C vs ASource of controlS: increased risk for follicular lymphoma TT vs. CC; TT vs. CT + CCNSWang \[[@CR50]\]19 studies 9,799 cases, 11,841 controlsSHMT C1420T, cancer riskAssociation between SHMT C1420T and cancer using genetic models of heterozygote, homozygote, dominant, recessive.NSRace/ethnicityS: decreased risk in Asian population TT vs. CC; CT vs. CC; TT + CT vs. CC; TT vs. CT + CCTumor typeS: decreased risk for colorectal cancer TT vs. CC; TT vs. CT + CCSource of control/populationNSWang \[[@CR51]\]8 case-control studies 3,232 cases 4,077 controlsSHMT C1420T, non-Hodgkin lymphomaAssociation between C1420T and non-Hodgkin lymphoma using genetic models of allele contrast, heterozygote, homozygote, dominant, recessive. T vs. CS: increased riskEthnicityNSTumor typeNSS = statistically significant (*P* \< 0.05)NS = not statistically significant (*P* \> 0.05) or confidence interval includes 1FA = folic acidGI = gastrointestinalGU = genitourinaryRCT = randomized control trialCRC = colorectal cancerMTHFR = methylenetetrahydrofolate reductase

Supplementation {#Sec3}
---------------

Several meta-analyses have evaluated the impact of folic acid (FA) supplementation on cancer risk using data from primary prevention trials for a number of conditions reporting cancer incidence. Two meta-analyses of Randomized Controlled Trials (RCTs) and a meta-analysis with 12 RCTs and 7 observational studies, evaluated the impact of FA supplementation, with or without other B vitamins, on cancer risk. Doses of FA ranged between 0.4 and 40 mg/day. Only one study used 5-methyltetrahydrofolate (5-MTHF), the metabolically active form of folate at a dose of 560 mcg/day. However, when that study was removed it did not change results. No significant effect of FA supplementation was found on total cancer risk in two of the analyses \[[@CR32]•, [@CR33]•\]. One analysis reported a "borderline significant" 7% increase in overall cancer risk; however, the confidence interval (CI) included 1 \[[@CR34]•\]. Two analyses also found no significant association between FA supplementation and risk of colorectal, prostate, lung, breast, or hematological cancers \[[@CR32]•, [@CR33]•\]; however, one found a 24% increased risk of prostate cancer \[[@CR34]•\]. One found no effect with less common types of cancer and cancers of unknown origin \[[@CR33]•\]; and another found a 53% lower risk of melanoma \[[@CR32]•\].

In subgroup analysis, Qin found a 10% increased risk of cancer in studies where \> 60% of participants were on lipid-lowering drugs and hypothesized that statin treatment interacting with homocysteine metabolism in the presence of FA supplementation may impact cancer risk \[[@CR32]•\]. Wien reported a 21% increased risk of cancer with doses between 0.4 and 1 mg/day, but not with doses higher than 1 mg/day and a 19% increased risk in smokers \[[@CR34]•\].

Additional analyses evaluating risk in specific cancer types found a significant 3% decrease in risk of renal cancer with 100-mcg FA supplementation in a dose-response analysis \[[@CR31]\]. When comparing highest with lowest intake from food fortification and supplements, two studies reported an inverse association and one study found no effect on risk of colorectal cancer \[[@CR35]--[@CR37]\].

Serum Levels {#Sec4}
------------

Zhang and colleagues found elevated homocysteine levels and folate deficiency, as determined by serum folate level, to be associated with increased overall risk of cancer in a meta-analysis of 83 case-control studies \[[@CR11]\]. Folate level was inversely associated with most cancer types except prostate, bladder, pancreatic, and breast. Protection was seen in studies from Europe, Asia, the Middle East, and Latin America, but not the USA or Australia. Zhao and colleagues found that the highest compared to lowest serum folate level was associated with decreased risk of esophageal cancer \[[@CR20]\].

Higher or at least adequate levels may also be protective for cervical cancer. Increased risk of cervical cancer was observed with deficiency per serum folate in Asian, but not American studies. Serum levels used to categorize deficiency were different between studies, and some were higher than what is reported in the literature, which may have impacted results. These findings need to be confirmed using consistent cutoffs categorizing deficiency \[[@CR28]\].

Two analyses found increased risk of prostate cancer when comparing highest with lowest serum folate levels. Both included five of the same nested case-control studies \[[@CR17], [@CR24]\]. One group included one additional case-control study and one retrospective case-control study \[[@CR17]\]. Wang's dose-response analysis reported a 4% increase in risk with each 5 nmol/L increase in serum folate \[[@CR24]\]. After removing a retrospective study that was contributing to significant heterogeneity, Tio's group found the association was still significant. The study removed was conducted in Jamaica, where risk was much higher with high levels, and the authors posed the question of whether or not folate may play a role in racial differences seen in prostate cancer risk \[[@CR17], [@CR24]\].

The studies in these analyses either compared tertile 3 to 1 or compared low level with high level. Low levels were between less than 4.82 nmol/L and less than 10.9 nmol/L and high between less than 10.3 and 58.2 nmol/L. Only one study found an association, but pooled results were consistent with that study. Serum folate was non-fasting, which could impact results and reflect recent intake. Some studies used a level barely considered adequate as the "high" category making it difficult to interpret these findings. The authors mentioned that there was a low incidence of cancers and could have impacted results \[[@CR24]\]. Future studies should use serial measurements of RBC folate with clear cutoffs to help clarify this association \[[@CR17]\].

Additional analyses found no association when comparing highest with lowest serum levels and risk of renal \[[@CR31]\], pancreatic \[[@CR22]\], breast \[[@CR14]\], or colon cancers \[[@CR29]\]. Chuang and colleagues found an inverse association for studies using radioimmunoassay, surfacing issues related to methods, including testing measurements, storage of samples and vitamin degradation, and variations in cohorts and study design \[[@CR29]\].

Cancer Types, Intake, and Risk {#Sec5}
------------------------------

Folate intake is associated with a protective effect for some cancers, little to no effect for others, and a potential for increased risk with higher intake. When comparing the highest to lowest intake of folate, higher intake was associated with a nearly 50% decreased risk for squamous cell carcinoma of the head and neck (HNSCC) \[[@CR18]\]; 35% reduced risk for oral cavity and pharyngeal (OPC) \[[@CR19]\]; 41% reduced risk for all histological types of esophageal \[[@CR21]\]; 34% reduction in pancreatic \[[@CR21], [@CR22]\]; and 16% reduction in bladder cancers \[[@CR25]\]. The prospective analysis for pancreatic cancer was only significant when a study was removed that had lower levels of folate intake then the other studies. That study had a mean high intake of 246 mcg/day, an amount below the recommended intake, compared to 350--700 mcg/day in other studies \[[@CR21]\]. Heavy alcohol use with low folate status was associated with 4 times the risk of OPC compared with low alcohol and high folate intake \[[@CR19]\].

Dose-response analyses have shown that every 100 mcg/day increase in folate intake was associated with a 4.3% decrease in risk of HNSCC \[[@CR18]\]; 12% decrease in risk of esophageal cancer in studies other than Asian and American studies \[[@CR20]\]; and a 7% lower risk of pancreatic cancer \[[@CR22]\].

There was no reduction in risk seen with lung cancer until one study with all females was removed due to heterogeneity. Then, a 10% reduction in risk was observed \[[@CR23]\]. The authors attributed this to a higher percentage of smokers in the males \[[@CR23]\]. Similarly, no protective effect comparing highest with lowest quantiles of folate intake for risk of ovarian cancer was found until a study was removed due to heterogeneity. Then, a 27% reduced risk was seen with higher intake \[[@CR26]\]. It should be noted that highest intake in the removed study had a cutoff that could have included intake below or at the Dietary Reference Intake (DRI) \[[@CR26]\].

Meta-analyses of studies for dietary folate and total folate intake found no association with risk of prostate cancer. Low intake in studies ranged from 123.8 mcg/day to 411 mcg/day (diet) and 551.9 mcg/day (total) and high intake reported as 235 mcg/day to 669 mcg/day (diet) and 934.1 mcg/day (total). In many studies, low and high diet intake are both below the recommended daily amount or the cutoffs for high with low overlap, making it difficult to discern a true cut point for risk if one does exist \[[@CR17], [@CR24]\].

Recent studies regarding folate intake have found little to no association between folate intake and breast cancer, with the exception of those comparing higher alcohol consumption with lower folate intake \[[@CR14]--[@CR16], [@CR52]\]. Chen et al. and Zhang et al. demonstrated a non-linear dose-effect relationship between dietary folate intake level and breast cancer risk \[[@CR14], [@CR15]\]. For prospective studies, Chen et al. showed a U-shaped dose-effect relationship for dietary folate intake level and breast cancer risk \[[@CR14]\]. There was a significantly decreased breast cancer risk with dietary folate intake between 153 and 400 mcg compared with those of \< 153 mcg, but there was not a statistically significant reduced risk with dietary folate intake \> 400 mcg compared to \< 153 mcg \[[@CR14]\]. For case-control studies, Chen et al. found that an increment of 100 mcg dietary folate per day showed a 9% reduction in breast cancer risk \[[@CR14]\]. Zhang et al. found a potential J-shape correlation between folate intake and breast cancer risk; daily folate intake of 200--320 mcg was associated with lower breast cancer risk, but the risk increased significantly with a daily folate intake \> 400 mcg \[[@CR15]\]. Liu et al. found that a 220 mcg/day increment in dietary folate intake was not associated with breast cancer risk \[[@CR16]\]. Studies varied in the incremental dose used to assess a dose-effect relationship.

Du and colleagues found a "marginal negative association" between total folate intake and risk of endometrial cancer \[[@CR27]\]. An 11% reduction in risk was observed between higher intake and risk; however, the finding was not statistically significant. Interestingly, the association was not found for retrospective studies conducted outside of N. America (11 out of 14 studies). In the highest category of folate intake, which ranged from 205.8 to 987.7 mcg between studies, they reported a 5% elevated risk for every 100 mcg/day increase in folate intake, suggesting a threshold effect. They also suggested that type II or non-estrogen-dependent cancers are more likely to be related to p53 mutations, DNA damage, and changes to cell proliferation, yet the type of endometrial cancer not distinguished in most studies \[[@CR27]\].

Gene Polymorphisms {#Sec6}
------------------

Gene variants associated with the folate metabolic pathway disturb nutrient bioavailability and contribute to a range of diseases. Methylenetetrahydrofolate reductase (MTHFR) directly affects DNA synthesis and methylation and has been associated with increased risk of certain cancers. In a meta-analysis of 134 case-control studies, the MTHFR C677T polymorphism was significantly associated with increased tumor risk \[[@CR38]\]. In stratified analysis of the same study, increased risks of stomach and esophageal cancer were observed and increased risk in Asian ethnicity was observed \[[@CR38]\]. Mutation of the 677 gene has also been associated with increased risk of lung, hepatocellular, breast, brain, and ovarian cancer in Asian populations and breast cancer in Turkish population \[[@CR7], [@CR12], [@CR26], [@CR39], [@CR42], [@CR44]\]. While no association was observed for MTHFR and oral cancer, subgroup analysis revealed a statistically significant increased risk in heavy versus non-heavy drinkers \[[@CR46]\]. Two meta-analyses showed no association between MTHFR C677T allele and glioma, while an increased risk of brain tumor and meningioma was associated with the heterozygous genotype \[[@CR41], [@CR42]\]. MTHFR TT has been shown to be positively associated with risk of thyroid cancer \[[@CR48]\] and increased risk of non-Hodgkin lymphoma in Caucasians \[[@CR49]\].

Conversely, MTHFR 677TT may have a protective effect against colorectal cancer, in aggressive forms of prostate cancer, and prostate and non-Hodgkin lymphoma among Asians \[[@CR30], [@CR45], [@CR49]\]. Similarly, a decreased risk of oral cancer has been associated with the MTHFR 677CT genotype in Asians \[[@CR46]\]. High total and dietary folate intake was inversely associated with colorectal cancer for the wild-type allele, whereas MTHFRTT showed a protective effect for colorectal with high total folate intake compared to low total folate intake \[[@CR30]\].

The presence of the MTHFR A1298C variant has been significantly associated with increased risk for cervical cancer, globally and among Asians \[[@CR40]\]. Homozygosity for A1298C in Asians has been associated with an increased risk of myeloid leukemia and non-Hodgkin lymphoma \[[@CR47], [@CR49]\]. Conversely, a decreased risk of liver cancer has been observed with the homozygous variant MTHFR 1298 CC overall and in Asian populations \[[@CR43], [@CR44]\].

Homozygosity for SHMT C1420T has been associated with a protective effect against colorectal cancer and overall cancer risk for Asian ethnicity \[[@CR50]\]. Another study found no association between colorectal cancer and SHMT; however, subgroup analysis showed a significant decreased cancer risk with low folate intake in the presence of SHMT1 variation. Folate intake level was not defined. A positive association was found between SHMT1 and risk for non-Hodgkin lymphoma \[[@CR51]\].

Conclusion {#Sec7}
==========

A number of factors need to be considered when evaluating and comparing studies, including limitations in the current literature. There is a great deal of heterogeneity in the populations studied, including geographical and ethnic differences, presence of polymorphisms, use of data from both pre- and post-fortification time periods, and inclusion of populations with and without fortification. Also, many studies relating to folate intake are observational and use a one-time food frequency questionnaire, which does not consider change in diet over time, and may not account for other lifestyle factors, including alcohol intake. Different methods and cutoffs are used to categorize highest compared to lowest intake and there is variability in serum levels, with a single serum level used to evaluate risk. Cutoffs overlap making it difficult to discern a true cut point if risk of one exists. The length of time for follow up varies between studies and may not be adequate to evaluate impact on risk. This makes it difficult to form a single conclusion regarding the impact of folate on cancer risk. However, there are populations who appear to be at risk due to either inadequate or excess intake.

Inadequate folate intake or deficiency, as measured by serum levels, may increase risk for cancer, including cancers of the head and neck \[[@CR18]\], oral cavity and pharynx \[[@CR19]\], esophagus \[[@CR21]\], pancreatic \[[@CR21], [@CR22]\], bladder \[[@CR25]\], and cervix. Low intake combined with high alcohol intake may also increase the risk of breast cancer. Gene polymorphisms may add to risk in certain ethnic groups. Clinicians should aim to optimize dietary folate intake and/or consider supplementing intake in individuals at risk for or with known deficiency, for example those with alcohol dependence or malabsorption. Prospective studies are needed to identify what level of folate intake is needed to correct deficiency based on gene status and evaluate whether or not nutrient remediation in high-risk populations can mitigate cancer risk.

In addition, more research is needed to help understand if the protective effects of folate are weaker in populations with a relatively higher intake level from mandatory fortification and/or supplementation. Population concerns regarding fortification and increased cancer risk are challenged in the current research. Fortification status in studies did not have any impact on risk with supplementation \[[@CR32]•, [@CR33]•\]. Fortification practices vary and increasing use of organic and gluten-free flours, which may not be fortified, may change population intake over time. More prospective, post-fortification work needs to be done in some populations. For example, the association between supplemental intake, elevated serum levels, and increased risk of prostate cancer should be explored in the context of gene variants. Clinicians should weigh the pros and cons of supplementation in the presence of adequate intake with individuals based on all risk factors for disease.

Finally, it is important to note that dozens of enzymes affect the efficiency of folate-related metabolic pathways, and polymorphisms in these enzymes may alter substrate availability of folate and/or other nutrients as well as gene expression. Future research efforts should be aimed at understanding how polymorphisms affect nutrient status in ethnic-specific populations, how nutrient remediation affects enzyme function in the presence of polymorphisms, and how these may influence risk \[[@CR53]\]. Also, it is important to remember that additional nutrients are involved in one-carbon metabolism. By studying folate intake or serum levels in isolation, we may be missing the critical role of synergy among nutrients. For the clinician, it is important to evaluate each case individually and consider overall diet pattern in the context of all internal and external aspects that impact disease risk.
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